Analysis of Profitability Ratios
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Biogen Inc., profitability ratios
Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Biogen Inc.’s gross profit margin ratio deteriorated from 2017 to 2018 and from 2018 to 2019. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Biogen Inc.’s operating profit margin ratio improved from 2017 to 2018 and from 2018 to 2019. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Biogen Inc.’s net profit margin ratio improved from 2017 to 2018 and from 2018 to 2019. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Biogen Inc.’s ROE improved from 2017 to 2018 and from 2018 to 2019. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Biogen Inc.’s ROA improved from 2017 to 2018 and from 2018 to 2019. |
Gross Profit Margin
Biogen Inc., gross profit margin calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Gross profit | 12,422,500 | 11,636,600 | 10,643,900 | 9,970,100 | 9,523,400 | |
| Revenues | 14,377,900 | 13,452,900 | 12,273,900 | 11,448,800 | 10,763,800 | |
| Profitability Ratio | ||||||
| Gross profit margin1 | 86.40% | 86.50% | 86.72% | 87.08% | 88.48% | |
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| Abbott Laboratories | 52.46% | 51.32% | 47.75% | 54.09% | — | |
| AbbVie Inc. | 77.64% | 76.44% | 75.05% | 77.25% | — | |
| Amgen Inc. | 80.38% | 81.80% | 81.33% | 80.99% | — | |
| Bristol-Myers Squibb Co. | 69.10% | 70.98% | 70.80% | 74.54% | — | |
| Eli Lilly & Co. | 78.85% | 73.81% | 73.46% | 73.35% | — | |
| Gilead Sciences Inc. | 78.86% | 77.61% | 82.97% | 85.77% | — | |
| Illumina Inc. | 69.63% | 69.01% | 66.35% | 69.48% | — | |
| Johnson & Johnson | 66.42% | 66.79% | 66.84% | 69.84% | — | |
| Merck & Co. Inc. | 69.87% | 68.06% | 68.16% | 65.10% | — | |
| Pfizer Inc. | 80.25% | 79.03% | 78.61% | 76.66% | — | |
| Regeneron Pharmaceuticals Inc. | 90.05% | 93.53% | 93.24% | 93.83% | — | |
| Vertex Pharmaceuticals Inc. | 86.84% | 86.56% | 88.95% | 87.64% | — | |
| Zoetis Inc. | 68.18% | 67.19% | 66.55% | 65.92% | — | |
Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).
1 2019 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × 12,422,500 ÷ 14,377,900 = 86.40%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Biogen Inc.’s gross profit margin ratio deteriorated from 2017 to 2018 and from 2018 to 2019. |
Operating Profit Margin
Biogen Inc., operating profit margin calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Income from operations | 7,042,600 | 5,888,600 | 5,344,200 | 5,150,400 | 4,891,000 | |
| Revenues | 14,377,900 | 13,452,900 | 12,273,900 | 11,448,800 | 10,763,800 | |
| Profitability Ratio | ||||||
| Operating profit margin1 | 48.98% | 43.77% | 43.54% | 44.99% | 45.44% | |
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| Abbott Laboratories | 14.21% | 11.94% | 6.30% | 15.27% | — | |
| AbbVie Inc. | 39.03% | 19.49% | 33.99% | 36.60% | — | |
| Amgen Inc. | 43.57% | 45.55% | 45.76% | 44.74% | — | |
| Bristol-Myers Squibb Co. | 22.62% | 22.69% | 17.39% | 23.83% | — | |
| Eli Lilly & Co. | 22.29% | 15.15% | 9.38% | 16.30% | — | |
| Gilead Sciences Inc. | 19.38% | 37.83% | 55.04% | 58.87% | — | |
| Illumina Inc. | 27.80% | 26.49% | 22.02% | 24.48% | — | |
| Johnson & Johnson | 24.15% | 24.27% | 24.07% | 28.72% | — | |
| Merck & Co. Inc. | 24.77% | 19.62% | 16.28% | 13.51% | — | |
| Pfizer Inc. | 25.46% | 26.10% | 25.92% | 22.73% | — | |
| Regeneron Pharmaceuticals Inc. | 28.10% | 37.77% | 35.41% | 27.38% | — | |
| Vertex Pharmaceuticals Inc. | 28.77% | 20.84% | 4.95% | 0.58% | — | |
| Zoetis Inc. | 31.42% | 31.12% | 32.15% | 28.48% | — | |
| Operating Profit Margin, Sector | ||||||
| Pharmaceuticals & Biotechnology | 25.89% | 24.29% | 25.36% | 28.18% | — | |
| Operating Profit Margin, Industry | ||||||
| Health Care | 18.67% | 17.79% | 18.39% | 19.66% | — | |
Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).
1 2019 Calculation
Operating profit margin = 100 × Income from operations ÷ Revenues
= 100 × 7,042,600 ÷ 14,377,900 = 48.98%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Biogen Inc.’s operating profit margin ratio improved from 2017 to 2018 and from 2018 to 2019. |
Net Profit Margin
Biogen Inc., net profit margin calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income attributable to Biogen Inc. | 5,888,500 | 4,430,700 | 2,539,100 | 3,702,800 | 3,547,000 | |
| Revenues | 14,377,900 | 13,452,900 | 12,273,900 | 11,448,800 | 10,763,800 | |
| Profitability Ratio | ||||||
| Net profit margin1 | 40.96% | 32.93% | 20.69% | 32.34% | 32.95% | |
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| Abbott Laboratories | 11.56% | 7.74% | 1.74% | 6.71% | — | |
| AbbVie Inc. | 23.69% | 17.36% | 18.82% | 23.22% | — | |
| Amgen Inc. | 35.32% | 37.25% | 9.08% | 35.27% | — | |
| Bristol-Myers Squibb Co. | 13.15% | 21.81% | 4.85% | 22.94% | — | |
| Eli Lilly & Co. | 37.27% | 13.16% | -0.89% | 12.90% | — | |
| Gilead Sciences Inc. | 24.35% | 25.16% | 18.03% | 45.07% | — | |
| Illumina Inc. | 28.28% | 24.78% | 26.38% | 19.29% | — | |
| Johnson & Johnson | 18.42% | 18.75% | 1.70% | 23.01% | — | |
| Merck & Co. Inc. | 21.01% | 14.71% | 5.97% | 9.85% | — | |
| Pfizer Inc. | 31.45% | 20.79% | 40.55% | 13.66% | — | |
| Regeneron Pharmaceuticals Inc. | 26.91% | 36.42% | 20.41% | 18.42% | — | |
| Vertex Pharmaceuticals Inc. | 28.27% | 68.80% | 10.59% | -6.58% | — | |
| Zoetis Inc. | 23.96% | 24.52% | 16.28% | 16.80% | — | |
| Net Profit Margin, Sector | ||||||
| Pharmaceuticals & Biotechnology | 23.19% | 19.80% | 12.42% | 20.64% | — | |
| Net Profit Margin, Industry | ||||||
| Health Care | 16.41% | 14.00% | 9.98% | 14.08% | — | |
Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).
1 2019 Calculation
Net profit margin = 100 × Net income attributable to Biogen Inc. ÷ Revenues
= 100 × 5,888,500 ÷ 14,377,900 = 40.96%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Biogen Inc.’s net profit margin ratio improved from 2017 to 2018 and from 2018 to 2019. |
Return on Equity (ROE)
Biogen Inc., ROE calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income attributable to Biogen Inc. | 5,888,500 | 4,430,700 | 2,539,100 | 3,702,800 | 3,547,000 | |
| Total Biogen Inc. shareholders’ equity | 13,343,200 | 13,039,600 | 12,612,800 | 12,140,100 | 9,372,800 | |
| Profitability Ratio | ||||||
| ROE1 | 44.13% | 33.98% | 20.13% | 30.50% | 37.84% | |
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| Abbott Laboratories | 11.86% | 7.76% | 1.54% | 6.82% | — | |
| AbbVie Inc. | — | — | 104.16% | 128.41% | — | |
| Amgen Inc. | 81.07% | 67.15% | 7.84% | 25.85% | — | |
| Bristol-Myers Squibb Co. | 6.66% | 35.07% | 8.58% | 27.55% | — | |
| Eli Lilly & Co. | 319.09% | 32.88% | -1.76% | 19.54% | — | |
| Gilead Sciences Inc. | 23.91% | 25.51% | 22.64% | 71.48% | — | |
| Illumina Inc. | 21.72% | 21.98% | 26.41% | 21.06% | — | |
| Johnson & Johnson | 25.42% | 25.60% | 2.16% | 23.49% | — | |
| Merck & Co. Inc. | 37.99% | 23.30% | 6.97% | 9.78% | — | |
| Pfizer Inc. | 25.77% | 17.59% | 29.88% | 12.12% | — | |
| Regeneron Pharmaceuticals Inc. | 19.08% | 27.91% | 19.51% | 20.13% | — | |
| Vertex Pharmaceuticals Inc. | 19.34% | 47.28% | 12.99% | -9.69% | — | |
| Zoetis Inc. | 55.39% | 65.35% | 48.81% | 55.21% | — | |
| ROE, Sector | ||||||
| Pharmaceuticals & Biotechnology | 29.60% | 27.94% | 14.55% | 23.11% | — | |
| ROE, Industry | ||||||
| Health Care | 23.37% | 21.29% | 13.59% | 18.84% | — | |
Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).
1 2019 Calculation
ROE = 100 × Net income attributable to Biogen Inc. ÷ Total Biogen Inc. shareholders’ equity
= 100 × 5,888,500 ÷ 13,343,200 = 44.13%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Biogen Inc.’s ROE improved from 2017 to 2018 and from 2018 to 2019. |
Return on Assets (ROA)
Biogen Inc., ROA calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Net income attributable to Biogen Inc. | 5,888,500 | 4,430,700 | 2,539,100 | 3,702,800 | 3,547,000 | |
| Total assets | 27,234,300 | 25,288,900 | 23,652,600 | 22,876,800 | 19,504,800 | |
| Profitability Ratio | ||||||
| ROA1 | 21.62% | 17.52% | 10.73% | 16.19% | 18.19% | |
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| Abbott Laboratories | 5.43% | 3.53% | 0.63% | 2.66% | — | |
| AbbVie Inc. | 8.84% | 9.58% | 7.50% | 9.01% | — | |
| Amgen Inc. | 13.13% | 12.64% | 2.48% | 9.95% | — | |
| Bristol-Myers Squibb Co. | 2.65% | 14.06% | 3.00% | 13.22% | — | |
| Eli Lilly & Co. | 21.17% | 7.36% | -0.45% | 7.05% | — | |
| Gilead Sciences Inc. | 8.74% | 8.57% | 6.58% | 23.70% | — | |
| Illumina Inc. | 13.70% | 11.87% | 13.81% | 10.81% | — | |
| Johnson & Johnson | 9.59% | 10.00% | 0.83% | 11.71% | — | |
| Merck & Co. Inc. | 11.66% | 7.53% | 2.72% | 4.11% | — | |
| Pfizer Inc. | 9.72% | 7.00% | 12.40% | 4.20% | — | |
| Regeneron Pharmaceuticals Inc. | 14.29% | 20.83% | 13.67% | 12.84% | — | |
| Vertex Pharmaceuticals Inc. | 14.15% | 33.57% | 7.43% | -3.87% | — | |
| Zoetis Inc. | 12.99% | 13.25% | 10.06% | 10.73% | — | |
| ROA, Sector | ||||||
| Pharmaceuticals & Biotechnology | 9.30% | 9.07% | 5.04% | 8.67% | — | |
| ROA, Industry | ||||||
| Health Care | 8.44% | 7.94% | 5.12% | 7.42% | — | |
Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).
1 2019 Calculation
ROA = 100 × Net income attributable to Biogen Inc. ÷ Total assets
= 100 × 5,888,500 ÷ 27,234,300 = 21.62%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Biogen Inc.’s ROA improved from 2017 to 2018 and from 2018 to 2019. |